MutantDx
  • HOME
  • OVERVIEW
  • PRINCIPALS
  • SCIENTIFIC ADVISORY BOARD
  • LICENSING OPPORTUNITIES
  • MARKET POTENTIAL
  • CLINICAL APPLICATIONS
  • PATENTS
  • WHY CANCER KILLS
  • MUTANTDX TECHNOLOGIES
  • COMPETITOR COMPARISONS
  • PUBLICATIONS
  • NEWS RELEASES/MARKETING MATERIALS
  • CONTACT US
Select Page

News Releases

  • MutantDx Raises the Bar for Early Cancer Detection
  • MutantDx Looks to Outlicense Ultrasensitive Mutation Detection Tech for Early Cancer Detection
  • MultiGen’s Modified Sanger Sequencing Takes Aim at Detecting Cancers, Infectious Diseases
  • MutantDx Liquid Biopsy enables cancer cure before symptoms develop!
  • Ultra-sensative cancer DNA test dramatically improves patient selection for chemotherapy
  • New Cancer DNA Test Shows Greater Sensitivity

Marketing Materials

  • Detection and Confirmation of EGFR del 747_A750
  • EGFR Mutations (L858R, T790M)
  • Detection and confirmation of Androgen receptor – ARV7
  • Braf TumorPlex™ – Detection and confirmation of BRAF V600E and V600K mutations
© Copyright MutantDx